In this episode, we explore Antiphospholipid Syndrome (APS) with Dr. Yu (Ray) Zuo, beginning with a clear, clinically grounded explanation before diving into the personal and scientific journey that drew him to this notoriously complex disease. Along the way, Dr. Zuo shares a case that forever changed how he understands APS, then takes us inside his latest Arthritis & Rheumatology study, where machine learning reveals hidden patterns that may reshape how we think about patients and risk. The conversation moves from bedside to bench and back again, tackling what AI can—and can't—do for rheumatology, where APS research is headed next, and what early investigators need to know to build impactful careers. 

In this episode, we sit down with Dr. William Harvey, the newly appointed President of the American College of Rheumatology and a dedicated volunteer of nearly 20 years. Dr. Harvey shares what it's like stepping into the presidency, the key priorities shaping the year ahead, and how the ACR is approaching strategy, advocacy, partnerships, and leadership during this pivotal moment for the field. 

In this week's episode, we dive into the ins and outs of the rheumatology musculoskeletal ultrasound certification process—what it takes to log 150 scans, meet CME requirements, and ultimately sit for the exam. We're joined by Dr. Liudmila Kastsianok, who shares her insights on how ultrasound is reshaping clinical practice, from enhancing diagnostic accuracy to opening new avenues in research. We also explore how incorporating ultrasound into routine care can deepen the physician-patient relationship and improve communication. Finally, Dr. Kastsianok offers her perspective on where the field is headed and why ultrasound is becoming an essential skill for the next generation of rheumatologists. 

Today we're talking about implicit bias with Dr Arin Reeves. What bias is, how it permeates our lives, how it can negatively impact our workforce, and its impact on clinical research and patient care. Most importantly, we discuss what we can do about our implicit biases to prevent them from causing damage. 

This week we welcome Dr. Alfred Kim to our show as we discuss B-Cell depleting therapies and how patients on these drugs may be more susceptible to COVID-19. During which, Dr. Kim takes us back to the beginning of the pandemic and how he and his patients initially managed the rituximab infusions, how and why people on this drug may be at increased risk of severe disease, the importance of vaccinations, and why they may not work for this patient population. Finally, we finish with Dr. Kim sharing with us important information on how to mitigate the risk of COVID-19 among people taking b-cell depleting therapies, now that there are new therapies for COVID-19 pre-exposure prophylaxis.  

Today's episode is all about mental health for today's healthcare professionals with our guest, Dr. Hanna Zembrzuska. She is a psychiatrist and rheumatologist and is a clinical assistant professor at The University of Iowa, holding appointments in the depts of internal medicine and psychiatry. We discuss everything from what burnout is, strategies to prevent/overcome it, the importance of having a sense of control within your medical practice and how to establish boundaries to coaching and support groups for physicians, as well as tips and tricks to maintain your mental health during busy clinic days. We then dive into how depression and anxiety can cause physical pain with rheumatic disease. 

Today, in this episode, we'll discuss the new "2021 Guideline for the Management of Kawasaki Disease", the mysterious triggers that cause KD, the use of therapies such as IVIG, steroids, infliximab, anakinra, and compare multisystem inflammatory disease in children, or MIS-C (a condition very similar to Kawasaki Disease that is triggered by SARS COV-2). Joining us today is Dr. Mark Gorelik, lead Author of the "2021 Guideline for the Management of Kawasaki Disease". He's an assistant professor of pediatrics at the Columbia University Vagelos College of Physicians and Surgeons, is a pediatric rheumatologist, an allergist and immunologist. His research focuses on vasculitis, including Kawasaki disease, and on immune dysregulation.   

In this episode, Dr. Kim Steinbarger, PT, MHS, DHSc, Asst. Professor at Husson University, and Talitha Black, an occupational therapist at Children's Hospital Los Angeles (CHLA), help us clarify some common misconceptions about exercise for people with rheumatic diseases. We'll discuss tips and strategies to increase physical activity for people of all ages, explore who would benefit from physical or occupational therapy. We'll discuss bracing, taping, and other strategies that people may use to reduce pain and improve function. 

• Tough Choices: Exploring Medication Decision-Making During Pregnancy and Lactation Among Women With Inflammatory Arthritis. ACR Open Rheumatology. 
• Improving Knowledge of Lactation Compatibility of Antirheumatic Medications Among Providers Who Care for Patients With Rheumatic Disease. ACR Open Rheumatology. 
• Improved Pregnancy Outcome in Patients With Rheumatoid Arthritis Who Followed an Ideal Clinical Pathway. ACR Arthritis Care & Research. 

In this episode of ACR on Air, we reach the final installment of our vasculitis guideline miniseries. Dr. Hausmann is once again joined by Dr. Sharon Chung, lead author of the 2021 ACR/VF guidelines for managing systemic vasculitis, to discuss Polyarteritis Nodosa (PAN). Dr. Chung weighs in on CTA over MRA for abdominal vascular imaging, and blind biopsy. Dr. Hausmann and Dr. Chung examine various patient scenarios for PAN symptoms and why they would meet the criteria for data testing. 

In this episode of ACR on Air, we continue into part two of our Vasculitis miniseries with Dr. Sharon Chung, lead author of the 2021 ACR/VF guidelines for managing systemic vasculitis. Dr. Chung addresses how the guidelines were developed, the use of use temporal artery biopsy, and the on-going challenges with treating Takayasu's arteritis. She also highlights the success of non-invasive ultrasound techniques in Europe for diagnosing Giant Cell Arteritis (GCA) and discusses the treatment approaches for GCA. 

In this episode, we preview ACR Convergence 2025 in Chicago this October with Dr. Greg Gardner, Chair of the Annual Meeting Planning Committee (AMPC). We'll explore key topics like emerging therapies, AI in rheumatology, and highlights such as the Practice Innovation Summit, Ultrasound Course, and Fellows In Training (FiT) Program. Dr. Gardner also discusses highlights such as, CAR T-cell therapies, new non-renal lupus guidelines, a Live Journals Club focused on Big Data and why this year's meeting is earlier on the calendar. Tune in for a sneak peek at what's to come! 

In this episode of ACR on Air we begin the first entry in our Vasculitis miniseries with Dr. Sharon Chung, where we take a detailed examination of the 2021 ACR/VF guidelines for managing systemic vasculitis. In part one of the series Dr. Chung will discuss the importance and creation of the guidelines along with the impact the author's hope to achieve. We then dive into the recommendations for ANCA-associated vasculitis, including: GPA, EGPA and MPA. We'll address controversial questions for treatment and the impacts that arise for COVID-19 vaccinations.

It's been seven months since the ACR released its COVID-19 Vaccine Clinical Guidance for Patients with Rheumatic and Musculoskeletal Diseases, and we continue to learn more about navigating COVID-19 in rheumatology patients. Some real-world data has become available on patient outcomes. The FDA has issued an EUA for 3rd doses of an available mRNA vaccine in certain immunocompromised patients. Antibody testing continues to be heavily debated. And monoclonal antibody treatment has received an EUA to be used as a prophylaxis measure in patients at high risk for developing severe COVID-19. Dr. Jeff Curtis, Chair of the ACR COVID-19 Vaccine Guidance Task Force, joins us to discuss these developments, updated task force recommendations, and more.

On episode 21, we discussed alternative therapies that providers and patients can consider to support treatment plans for rheumatic diseases. On this episode,  Dr. Monica Guma joins the show to talk about how diet may impact these conditions, positively or negatively.  

The host, Dr. Guma nor the ACR suggest that patients with rheumatic conditions forgo traditional treatment plans recommended by trained rheumatologists and rheumatology health professionals. Patients should continue to see their rheumatologist to discuss complements to their treatment plan.

So, what are we talking about today? A topic that comes up often between providers and patients—alternative and integrative therapies to help treat rheumatic conditions.  Dr. Chenchen Wang joins the show to talk about a few of the popular therapies available for common conditions, address a few myths, and offer insight on how rheumatologists can support patients interested in these alternative options.  

While we are taking time to discuss this popular topic, the host, Dr. Wang nor the ACR are suggesting that patients with rheumatic conditions forgo traditional treatment plans recommended by trained rheumatologists and rheumatology health professionals. Patients should continue to see their rheumatologist for updates or additions to their treatment plan. 

This month, our host takes a look back on the telemedicine journey many health care providers and patients navigated in 2020. Dr. Christine Peoples and Dr. Aruni Jayatilleke join as guests sharing their experiences and tips on digitally treating patients with rheumatic diseases.

This show is a special one and covers a topic that so many of you have been asking about! The American College of Rheumatology just released its guidance on the COVID-19 vaccine for patients with rheumatic diseases, and we have the lead author, Dr. Jeff Curtis, on with our host to discuss the research and recommendations.   

Throughout the show, you will hear Dr. Curtis the ACR's recommendation that all patients with rheumatic diseases should get the vaccine and that it does not matter which one you get—just make sure your second dose is by the same brand. Bottom line: get whichever one is available to you as soon as you can get it.

They also discuss the process of developing the ACR guidance, the experts involved including epidemiologists, rheumatologists, and infectious disease clinicians; and how they plan to keep the document updated.

And finally, they discuss the safety and efficacy of the vaccines despite how rapidly they were developed, the low risk of disease flares, and the importance of ongoing research on this topic.

This is the episode you want to listen to NOW!

This month's show focuses on advocacy in the rheumatology space. Our host chats with Lennie Shewmaker McDaniel, director of congressional affairs for the ACR; and Amanda Grimm Wiegrefe, the ACR's director of regulatory affairs about advocacy wins and losses for 2020, the upcoming priorities for 2021, and how listeners can get involved.

This month's show features a guest author discussing, Dr. Yusuf Yazici, discussing his team's efforts to create a drug treatment for osteoarthritis. The study was published in the American College of Rheumatology's journal, Arthritis & Rheumatology.

This month we're giving you a preview of ACR Convergence 2020, the ACR's annual meeting, which will be held Nov. 5 – 9 in an all-virtual environment. Our host chats with Dr. Vicki Shanmugam and Dr. Swamy Venuturupalli about the shift to a virtual event this year, what's changing and staying the same, must attend sessions including special COVID-19 discussions and what participants can expect from this all-encompassing experience. 

In recognition of Rheumatic Disease Awareness Month this September, this episode explores the critical yet often underutilized role of exercise in the management of rheumatic diseases. We examine how structured movement—ranging from step counts to resistance training—can significantly alter the trajectory of pain, function, and overall disease progression. Our discussion offers practical strategies for helping patients integrate physical activity into their daily routines, with a focus on starting gradually and maintaining consistency. We also address the heightened cardiovascular risks associated with rheumatoid arthritis and how targeted exercise interventions can mitigate these risks. Finally, we delve into fall prevention tactics and the use of technology and interdisciplinary care teams to set achievable, patient-centered goals that physical therapists can effectively support. 

It's Rheumatic Disease Awareness Month, RDAM for short, and in this episode, we're talking with Dr. Kanika Monga about a few of the 100+ rheumatic diseases, the 54 million Americans with a rheumatic condition and the results of a nationwide patient survey. RDAM is hosted every September by the American College of Rheumatology and its Simple Tasks™ awareness campaign.

ACR on Air is back for Season 2 with a very important topic for the rheumatology specialty. Listen as our host chats with Dr. Lisa Sammaritano and Dr. Ware Branch about reproductive health for patients with rheumatic diseases.

The special COVID-19 series continues with a discussion on how to keep your practice going during this pandemic. Our host chats with Dr. Chris Phillips, who runs a solo practice in Kentucky, and Dan Redinger, an ACR staffer who is keeping his eye on the federal government's COVID-19 stimulus package. Listen as they share best practices and tips for health care providers during this unprecedented time.

In the midst of the COVID-19 pandemic, rheumatologists and rheumatology health professionals have found themselves in an unprecedented situation where the rise of telehealth has been key to treating their patients. In this episode of ACR on Air, our host will speak with two ACR experts, Dr. Jay Mehta and Antanya Chung, about telehealth best practices.

In light of the current COVID-19 pandemic, the American College of Rheumatology has dedicated the next few episodes of ACR on Air to the challenges that have arisen, along with information about the available resources and guidance . The first episode in this special series focuses on drug shortages including hydroxychloroquine (HCQ) and chloroquine.

In this episode, our guest, Dr. Daniel Solomon, takes us on a journey through the life cycle of a manuscript and getting publishing. With more than 400 published articles under his belt, Dr. Solomon offers key tips on writing and submitting your work, how to promote your research, spotting predatory journals and more. He also shares valuable insight on publishing trends he's seen over the past 25 years.

The final 2019 ACR/ARP Annual Meeting edition of Hot Topics is here. Dr. Suleman Bhana and Dr. Ali Duarte-Garcia chat with our host, Dr. Jon Hausmann, about the last few studies featured in press conferences at the meeting.

The ACR is back with another special 2019 ACR/ARP Annual Meeting Hot Topics edition. Our host, Dr. Jon Hausmann, is joined by guest hosts Dr. Suleman Bhana and Dr. Ali Duarte-Garcia to discuss more of the studies featured in the Annual Meeting press conferences.

In this special Hot Topics episode, our host and guests discuss more of the studies featured in the 2019 ACR/ARP Annual Meeting press conferences.

The ACR is back with a special 2019 ACR/ARP Annual Meeting Hot Topics edition. Our host, Dr. Jon Hausmann, along with Drs. Suleman Bhana and Paul Sufka, discuss a few of the studies featured in the Annual Meeting press conferences.

It's been over two decades since the American College of Rheumatology (ACR) last released comprehensive treatment guidelines for systemic lupus erythematosus (SLE), and much has changed. In this episode, we're joined by Dr. Lisa Sammaritano to discuss the forthcoming 2025 ACR Guidelines for the Treatment of SLE. These updated recommendations reflect a significant evolution in our approach to lupus care, from the growing range of therapeutic options to a stronger emphasis on patient engagement and minimizing steroid toxicity. We'll dive into how the guidelines tailor treatment across diverse organ systems and patient populations, and what clinicians need to know to effectively incorporate these updates into their practice. 

Episode 4 is a continuation of our series focused on value-based care and how to measure quality of care. Our guest host, Dr. Vaneet Sandhu, will chat with Dr. Lisa Suter about quality measurement and improvement , and what that means for the rheumatology specialty.

In this episode, Dr. Hausmann and his guests, Dr. Colin Edgerton, chair of the ACR's committee on rheumatologic care and Dr. Angus Worthing, chair of the ACR's government affairs committee, take listeners on a journey into value-based care and how it impacts the rheumatology profession.

This episode, our host talks with Dr. Sheila Angeles - Han, lead investigator on the JIA Uveitis guidelines. He also chats with Barbara Slusher, MSW, PA-C about how PAs/NPs help with the rheumatology workforce shortage.

This episode is a special edition called Hot Topics where our host Dr. Jon Hausmann chats with Dr. Suleman Bhana and Dr. Paul Sufka about intriguing articles from ACR journals.

In this episode, we're joined by Karen Durrant, founder of the Autoinflammatory Alliance, who shares her powerful journey from a determined parent seeking a diagnosis for her child to the leader of a global patient advocacy movement. What began as a personal quest has evolved into an international network supporting thousands affected by autoinflammatory diseases. Karen discusses how her collaboration with Dr. Fatma Dedeoglu, a leading pediatric rheumatologist, helped bridge the gap between patient experience and medical research—ultimately contributing to the development of international clinical guidelines that are transforming care for rare disease patients worldwide. 

Autoinflammatory Alliance

Systemic Autoinflammatory Disease (SAID) Support

Autoinflammatory Alliance: Coparison Chart

In this episode, we're joined by myositis expert Dr. Brian Feldman to explore Juvenile Dermatomyositis (JDM). We cover its clinical presentation, key diagnostic clues, and the workup including labs and imaging. We examine the MDA5 variant, known triggers, and non-pharmacologic management strategies. Dr. Feldman also addresses the high-stakes scenario of JDM-associated rapidly progressive interstitial lung disease, offering insights into pathophysiology, imaging, and aggressive early treatment. The episode concludes with a look at the field's questions that remain. 

In this episode, we're joined by Dr. Dana DiRenzo to explore groundbreaking developments in the treatment of Sjögren's Disease. For the first time, therapies like BAFF blockade, CD40 ligand inhibitors, and FcRn antagonists appear poised to change the course of the disease—moving beyond symptom management to potential disease modification. We delve into the underlying science, current clinical trials, and tackle the big question: how early is early enough to begin treatment? Dr. DiRenzo also shares her expert perspective on holistic symptom management through what she calls the "4 Pillars of Health," offering practical strategies for improving quality of life for those living with Sjögren's. 

In this episode, we take the leap from the structured world of rheumatology fellowship into the dynamic, often unpredictable landscape of private practice. Dr. J. Thomas Berry shares his personal journey, offering an honest and insightful look at the transition. From the practical differences between academic and private settings to the business learning curve, patient care dynamics, and how he stays clinically sharp, this conversation is a must-listen for fellows preparing to enter independent practice 

In this episode, we examine Behcet's Disease—a rare, multisystem inflammatory disorder that continues to challenge traditional frameworks of autoimmunity and vasculitis. Dr. Johannes Nowatzky joins us to discuss the disease's hallmark features, including recurrent mucocutaneous ulcers and ocular involvement, as well as its geographic distribution and genetic associations. We explore the diagnostic difficulties posed by its heterogeneous presentation and symptom overlap with other conditions, and the rationale behind individualized, often multidisciplinary treatment strategies. This conversation offers valuable insights into a condition that remains as enigmatic as it is clinically significant. 

In this episode, we deliver a critical update on the rapidly evolving legislative landscape impacting rheumatology. We explore the intense policy battles shaping the future of the field, including steep Medicare reimbursement cuts threatening the survival of many practices. We also examine the ongoing challenges posed by pharmacy benefit managers (PBMs) and the growing uncertainty around research funding. Joining us is a special guest, Lennie Shewmaker McDaniel, JD, who brings a firsthand perspective from Capitol Hill, shedding light on what it truly takes to advocate for our patients and the profession in today's complex policy environment. 

In this episode, our expert guest challenges a common assumption by explaining why the T-score—despite being central to osteoporosis diagnosis—is surprisingly easy to misinterpret. He walks us through how to read a DEXA scan like a detective, highlighting subtle clues that can dramatically improve diagnostic accuracy for your patients. Once osteoporosis is identified, the conversation turns to clinical decision-making: how to choose between anabolic agents, denosumab, and bisphosphonates, and why that choice depends on thoughtful risk stratification and patient-specific comorbidities. We also dive into the often-overlooked importance of sequencing osteoporosis medications correctly, including a compelling discussion on why starting with an anabolic agent may offer greater long-term benefits than reserving it as a last-line option. 

In this episode, we examine the evaluation of pain in patients with chronic inflammatory arthritis, with particular attention to spondyloarthritis and its clinical overlap with fibromyalgia. We explore why some patients continue to report persistent pain despite well-controlled inflammation, and the importance of distinguishing between active inflammatory disease and centralized pain syndromes such as fibromyalgia. Join us as we unpack the diagnostic nuances that can significantly impact patient care. 

This episode explores the evolving role of GLP-1 agonists in rheumatology, highlighting their potential to influence weight, inflammation, and overall disease activity. Our guest expert unpacks how adipose tissue contributes to systemic inflammation and why managing body weight is crucial in the treatment of rheumatic diseases. We delve into the underlying science, real-world clinical applications, and the exciting future of incorporating GLP-1 therapies into comprehensive rheumatologic care—offering fresh insight into a therapeutic class with game-changing potential.